Cargando…

Metastatic Pheochromocytomas and Abdominal Paragangliomas

CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor malignant potential; about 10% to 15% of pheochromocytomas and up to 50% of abdominal paragangliomas will exhibit metastatic behavior. EVIDENCE ACQUISITION: Extensive searches in the PubMed database with various combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Granberg, Dan, Juhlin, Carl Christofer, Falhammar, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063253/
https://www.ncbi.nlm.nih.gov/pubmed/33462603
http://dx.doi.org/10.1210/clinem/dgaa982
_version_ 1783681920551354368
author Granberg, Dan
Juhlin, Carl Christofer
Falhammar, Henrik
author_facet Granberg, Dan
Juhlin, Carl Christofer
Falhammar, Henrik
author_sort Granberg, Dan
collection PubMed
description CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor malignant potential; about 10% to 15% of pheochromocytomas and up to 50% of abdominal paragangliomas will exhibit metastatic behavior. EVIDENCE ACQUISITION: Extensive searches in the PubMed database with various combinations of the key words pheochromocytoma, paraganglioma, metastatic, malignant, diagnosis, pathology, genetic, and treatment were the basis for the present review. DATA SYNTHESIS: To pinpoint metastatic potential in PPGLs is difficult, but nevertheless crucial for the individual patient to receive tailor-made follow-up and adjuvant treatment following primary surgery. A combination of histological workup and molecular predictive markers can possibly aid the clinicians in this aspect. Most patients with PPGLs have localized disease and may be cured by surgery. Plasma metanephrines are the main biochemical tests. Genetic testing is important, both for counseling and prognostic estimation. Apart from computed tomography and magnetic resonance imaging, molecular imaging using (68)Ga-DOTATOC/DOTATATE should be performed. (123)I-MIBG scintigraphy may be performed to determine whether (131)I-MIBG therapy is a possible option. As first-line treatment in patients with metastatic disease, (177)Lu-DOTATATE or (131)I-MIBG is recommended, depending on which shows best expression. In patients with very low proliferative activity, watch-and-wait or primary treatment with long-acting somatostatin analogues may be considered. As second-line treatment, or first-line in patients with high proliferative rate, chemotherapy with temozolomide or cyclophosphamide + vincristine + dacarbazine is the therapy of choice. Other therapies, including sunitinib, cabozantinib, everolimus, and PD-1/PDL-1 inhibitors, have shown modest effect. CONCLUSIONS: Metastatic PPGLs need individualized management and should always be discussed in specialized and interdisciplinary tumor boards. Further studies and newer treatment modalities are urgently needed.
format Online
Article
Text
id pubmed-8063253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80632532021-04-28 Metastatic Pheochromocytomas and Abdominal Paragangliomas Granberg, Dan Juhlin, Carl Christofer Falhammar, Henrik J Clin Endocrinol Metab Mini-Reviews CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor malignant potential; about 10% to 15% of pheochromocytomas and up to 50% of abdominal paragangliomas will exhibit metastatic behavior. EVIDENCE ACQUISITION: Extensive searches in the PubMed database with various combinations of the key words pheochromocytoma, paraganglioma, metastatic, malignant, diagnosis, pathology, genetic, and treatment were the basis for the present review. DATA SYNTHESIS: To pinpoint metastatic potential in PPGLs is difficult, but nevertheless crucial for the individual patient to receive tailor-made follow-up and adjuvant treatment following primary surgery. A combination of histological workup and molecular predictive markers can possibly aid the clinicians in this aspect. Most patients with PPGLs have localized disease and may be cured by surgery. Plasma metanephrines are the main biochemical tests. Genetic testing is important, both for counseling and prognostic estimation. Apart from computed tomography and magnetic resonance imaging, molecular imaging using (68)Ga-DOTATOC/DOTATATE should be performed. (123)I-MIBG scintigraphy may be performed to determine whether (131)I-MIBG therapy is a possible option. As first-line treatment in patients with metastatic disease, (177)Lu-DOTATATE or (131)I-MIBG is recommended, depending on which shows best expression. In patients with very low proliferative activity, watch-and-wait or primary treatment with long-acting somatostatin analogues may be considered. As second-line treatment, or first-line in patients with high proliferative rate, chemotherapy with temozolomide or cyclophosphamide + vincristine + dacarbazine is the therapy of choice. Other therapies, including sunitinib, cabozantinib, everolimus, and PD-1/PDL-1 inhibitors, have shown modest effect. CONCLUSIONS: Metastatic PPGLs need individualized management and should always be discussed in specialized and interdisciplinary tumor boards. Further studies and newer treatment modalities are urgently needed. Oxford University Press 2021-01-19 /pmc/articles/PMC8063253/ /pubmed/33462603 http://dx.doi.org/10.1210/clinem/dgaa982 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Mini-Reviews
Granberg, Dan
Juhlin, Carl Christofer
Falhammar, Henrik
Metastatic Pheochromocytomas and Abdominal Paragangliomas
title Metastatic Pheochromocytomas and Abdominal Paragangliomas
title_full Metastatic Pheochromocytomas and Abdominal Paragangliomas
title_fullStr Metastatic Pheochromocytomas and Abdominal Paragangliomas
title_full_unstemmed Metastatic Pheochromocytomas and Abdominal Paragangliomas
title_short Metastatic Pheochromocytomas and Abdominal Paragangliomas
title_sort metastatic pheochromocytomas and abdominal paragangliomas
topic Mini-Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063253/
https://www.ncbi.nlm.nih.gov/pubmed/33462603
http://dx.doi.org/10.1210/clinem/dgaa982
work_keys_str_mv AT granbergdan metastaticpheochromocytomasandabdominalparagangliomas
AT juhlincarlchristofer metastaticpheochromocytomasandabdominalparagangliomas
AT falhammarhenrik metastaticpheochromocytomasandabdominalparagangliomas